Pruritus Associated with Targeted Anticancer Therapies and Their Management

Wu, Jennifer; Lacouture, Mario E.

doi:10.1016/j.det.2018.02.010

Cited by 30 publications

(21 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 The most effective prevention is through gentle skin care, including proper cleaning and the use of a moisturizer. 29…”

Section: Pruritus On Unchanged/normal-appearing Skinmentioning

confidence: 99%

“…11 Other treatments include antidepressants and systemic corticosteroids. 29 Mild BP may respond to potent topical corticosteroids; however, most BP treatment involves interruption of CPI therapy and initiation of systemic steroids. 57 In idiopathic BP, oral doxycycline has been shown to be equivalent to systemic steroids and is preferred owing to its superior safety profile.…”

Section: Approach To Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Immune-related cutaneous adverse events due to checkpoint inhibitors

Wang

Kraehenbuehl

Ketosugbo

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

Cutaneous toxicities are some of the most frequent immune-related cutaneous adverse events (ircAEs) with checkpoint inhibitors.Although the most common ircAEs include nonspecific maculopapular rashes, vitiligo, and lichenoid dermatitis, other ircAEs include bullous dermatosis and psoriasiform dermatitis. Severe cutaneous complications such as drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis are rare.Both cytotoxic T lymphocyteeassociated antigen-4 and programmed cell death protein 1/programmed death ligand 1 inhibitors acting at different stages of T-cell activation can result in a multitude of ircAEs, with T lymphocytes likely playing a key role.Allergists/immunologists need to be familiar with these ircAEs because their incidence will increase with the ever-expanding use of checkpoint inhibitors, and patients will be referred for suspected drug allergies.

show abstract

“…28 The most effective prevention is through gentle skin care, including proper cleaning and the use of a moisturizer. 29…”

Section: Pruritus On Unchanged/normal-appearing Skinmentioning

confidence: 99%

Section: Approach To Treatmentmentioning

confidence: 99%

Immune-related cutaneous adverse events due to checkpoint inhibitors

Wang

Kraehenbuehl

Ketosugbo

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Deep painful fissures are most often seen in the area of fingertips, heels, periungual skin and dorsal surface of the interphalangeal joints (39). Pruritus often coexists with xerosis (50%) and papulopustular rash (62%), and also commonly accompanies rash at onset (40). Similarly, paronychia frequently accompanies papulopustular rash.…”

Section: The Distribution and Typical Time Course Of Skin Appearancementioning

confidence: 99%

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors

Peng

Zhang

et al. 2018

BST

View full text Add to dashboard Cite

The past decades have witnessed a rapid increase in the use of molecularly targeted therapies. One class of agents includes the epidermal growth factor receptor inhibitors (EGFRIs), which afford patients longer progression-free survival (PFS) times, especially among non-small cell lung cancer (NSCLC) and metastatic colorectal carcinoma (mCRC). Certain adverse effects, particularly skin toxicity, are mainly manifested as rash, xerosis, pruritus, nails changes, hair changes and mucositis. Previous studies reported the adverse events occurred based on the cutaneous inflammation reaction. Treatment recommended glucocorticoids and antibiotics. It is suggested that skin toxicity is an important issue because it usually affects patients' quality of life (QoL) and still causes dose reduction or discontinuation of targeted therapies. For these reasons, more and more oncologists and dermatologists recognize the importance of recognition and management of skin toxicities with the expansion in availability of EGFRIs. In this review, we conducted a systematic review of recent data to examine the types and frequencies of dermatologic toxicities associated with anti-epidermal growth factor receptor (EGFR) therapies in NSCLC and mCRC. In addition, we would like to explore the management and treatment options currently used by clinicians based on the possible mechanism.

show abstract

“…Along with the expansive development and use of targeted tumour therapies, numerous reports have emerged about therapy-associated chronic pruritus (48)(49)(50)(51)(52). The neurokinin-1-antagonist aprepitant seems to have antipruritic potential in such cases (53).…”

Section: Drug-induced Itchmentioning

confidence: 99%

Non-dermatological Challenges of Chronic Itch

Kremer¹,

Mettang²,

Weißhaar³

2020

Acta Derm Venerol

View full text Add to dashboard Cite

Itch (medical term: pruritus) is an unpleasant sensation occurring in many skin diseases, but also in a variety of systemic, neurological, and psychogenic/psychosomatic disorders, or is caused by drug intake. These patients usually present with normal-looking skin or chronic scratch lesions of variable degree, including the clinical picture of chronic prurigo. This review focusses on the systemic causes of chronic itch, in particular liver disease, chronic renal failure, haematological disorders and adverse reactions of drug use. Furthermore, a diagnostic approach is presented, and effective, multimodal treatment options for the different systemic causes are summarized. Chronic itch occurs in many skin diseases, but also in a variety of systemic, neurological, and psychogenic/ psychosomatic disorders, or is caused by drug intake. When several diseases or causes co-exist, chronic itch is categorized as "mixed origin". These patients present with unaltered skin or with chronic scratch lesions including chronic prurigo. Precise diagnostics are necessary to evaluate the underlying aetiology, to enable identification of the best treatment available, and to improve patients' quality of life. This is of particular relevance in elderly people in whom chronic itch is often of systemic or mixed origin. Xerosis cutis is a frequent cofactor contributing to chronic itch of nondermatological origin. Treatment is frequently multimodal, considering age, comorbidities, current drug intake, quality and intensity of itch. With regard to the demographic situation of the population, characterized by increasing life expectancy and polypharmacy, itch of non-dermatological origin will represent an increasing medical challenge in the future.

show abstract

Pruritus Associated with Targeted Anticancer Therapies and Their Management

Cited by 30 publications

References 50 publications

Immune-related cutaneous adverse events due to checkpoint inhibitors

Immune-related cutaneous adverse events due to checkpoint inhibitors

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors

Non-dermatological Challenges of Chronic Itch

Contact Info

Product

Resources

About